A Phase 1 Relative Bioavailability Study of Ambrisentan and Tadalfil Fixed Dose Combination Tablets in Healthy Subjects

Clinical trial NCT02688387 · COMPLETED

Trial details

NCT number: NCT02688387
Sponsor: GlaxoSmithKline
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Hypertension, Pulmonary

Start date: 2016-03-18
Primary completion: 2017-08-04
Enrollment: 112

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.